PubMed Health⌕ Search

Biomedical subjects

E Tanner

Publications and source records attributed to E Tanner.

At least 19 recordsLinked to original sources

Nonfatal systemic allergic reactions induced by skin testing and immunotherapy.

Skin testing and immunotherapy with allergens can induce systemic allergic reactions. In order to identify factors associated with systemic allergic reactions, a prospective study was conducted from 1976-1989 with more than 10,000 patients being tested and a total of 513,368 injections being recorded. Our study showed that the probability of inducing systemic allergic reactions by skin testing was less than 0.02% and the probability of systemic allergic reactions caused by immunotherapy was 2.9%. The female to male ratio was 3 to 2. The highest incidence of systemic allergic reactions was in patients between the ages of 16 to 39 years of age. The majority of systemic allergic reactions occurred when patients were on increasing doses rather than maintenance doses. More than 95% of systemic allergic reactions were associated with pollens and most of them happened between the concentration of 100 and 1000 PNU/mL. There was no increased incidence during grass or ragweed pollination seasons in those patients who received grass or ragweed injections during the respective seasons. Only 50% of systemic allergic reactions developed within 30 minutes after injections. The three most important factors determining the incidence of systemic allergic reactions are the type of allergens, the "rate" of increase of allergen concentrations, and sensitivity of the patients to allergens. The prick test at initial allergy assessment can be used to "rule out," with a high degree of certainty, the likelihood of systemic allergic reactions. The prick test is easy to perform and it is cost-effective. Prick tests and RAST together are helpful in identifying the patients and the allergens at higher risk of systemic allergic reactions.

Adolescent↗

[Effect of propyphenazone on drug biotransformation in the liver. A comparison with phenylbutazone using the aminopyrine breath test].

By means of the aminopyrine breath analysis the influence of phenylbutazone, propyphenazone and of the combination preparation Wofapyrin "new" on the aminopyrine-N-demethylation, a hepatic microsomal performance of biotransformation in patients with diseases of the rheumatic circle of forms was examined. The enzyme-inducing effect of phenylbutazone known from literature could be confirmed. On the other hand despite a relatively highly dosed one-week treatment propyphenazone did not lead to changes of the demethylation capacity of the liver in the majority of the patients. In individual cases increases of the capacity are possible. In general, however, the doses of propyphenazone usual in the practice for the treatment of acute feverish infections no disturbing effects of induction or inhibition on the metabolic liver functions represented by the amino-N-demethylation are to be expected. The enzyme-inducing effect of Wofapyrin "new" is to be ascribed to the phenyl-butazone component.

Aged↗

A primate model for the evaluation of antihistamines.

Studies of the efficacy of antihistamines in treating human upper airway pathology are difficult to design and conduct. In part, this is the result of a lack of objective measures of the nasal response. The purpose of this study was to develop a monkey model for the objective evaluation of antihistamine effectiveness and, using this model, to study the efficacy of cetirizine. Computer-assisted active anterior rhinomanometry was used to assess nasal airway resistance (NAR) before and after a nasal histamine provocation in conscious rhesus monkeys (Macaca mulatta). To establish dose-response relationships for oral antihistamines in monkeys, we measured the suppression of wheal-and-flare reactions by two such agents, oral cetirizine (CET) 0.1 to 1 mg/kg and chlorpheniramine (CHL) 0.07 to 0.2 mg/kg. The decreases in wheal sizes were maximal 60 to 120 minutes after CET 1.0 mg/kg (90%), and after CHL 0.2 mg/kg (70%). The four monkeys were challenged intranasally with increasing histamine doses (0.5, 1, 5, and 10 mg). The NAR was measured 15 minutes after each dose. At least three days later and 90 minutes after oral pretreatment with either CET 1 mg/kg or CHL 0.2 mg/kg, the intranasal challenges were repeated. Postchallenge NAR data are given as the percent increase from the baseline NAR values. The four monkeys studied had coefficients of variation of 13%, 15%, 16%, and 26% respectively for baseline studies. Mean percent increases in NAR +/- standard deviation were 14% +/- 0.4%, 47% +/- 10.0%, 45% +/- 3.0%, and 72% +/- 6.0% after intranasal challenge with 0.5, 1, 5, and 10 mg of histamine, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Oral↗

Diclofenac and piroxicam in a double-blind trial results and methodological problems. Working Party of the Society for Rheumatology of the GDR for the Testing of Anti-rheumatic Drugs.

Diclofenac (150 mg/d) and piroxicam (20 mg/d) were compared in a cross-over trial with 12-day periods of double-blind treatment and 3-day wash-out periods. The following open phase of the trial lasted for two months and served to assess the tolerance. For this the dosage of diclofenac was reduced to 100 mg/d. 134 volunteers from 5 departments of rheumatology participated in the study. Statistical analysis showed that the two groups were of homogenous composition and that--with certain limitations--the necessary assumptions for the evaluation as a cross-over experiment were fulfilled. All tests used to determine the efficacy showed approximately parallel improvement with both formulations and in the wash-out phase this was followed by marked deterioration. The sum of the parameters for individual improvement showed a tendency in favour of piroxicam. However, clear superiority of one trial formulation over the other with respect to efficacy or tolerance could not be demonstrated by the statistical analysis.

Adult↗

[Methodological error in clinical lysozyme determinations].

In 152 sera and 40 synovial fluids of 192 patients from 3 different diagnostic groups the level of muramidase was studied comparatively with the lysoplate method. Despite the similar correlations of mean values and standard deviations of the results in the single groups, en detail these are significantly different. With an increasing mean value of 1 U (mg/l) the standard deviation is elevated by 0.1-0.25 U, for an elevation of s by 1 U mean varied between 3.8 and 9.7 U. This might be of interest for the clinical interpretation esp. of low muramidase values.

Humans↗

[Clinical significance of complement values in rheumatic diseases].

The more than 10-year experiences with complement examinations in rheumatic diseases are described: Manifold determinations of the complement in the course of the disease may be valuable diagnostic means, taking into consideration acknowledged criteria of the diagnosis in forms of rheumatic diseases with increasing immune pathogenesis. Particularly important are repeated determinations in the synovial fluid with references to a rheumatoid arthritis and in the serum in systemic lupus erythematodes as well as for the limitation of the earliest manifestations of a systemic sclerodermia with positive proof of antinuclear factors.

Complement System Proteins↗

[Intra-articular therapy with radionuclides].

The 12-year experiences of a working team with the intraarticular radiogold therapy in persisting synovialitides of chronic rheumatic diseases and resistant irritation phases of arthroses are supplementarily described and a critical valuation is performed. Finally practical conclusions for the local joint therapy are made, taking into consideration also the experiences of other investigators.

Adult↗